Dexpramipexole - Knopp Biosciences

Drug Profile

Dexpramipexole - Knopp Biosciences

Alternative Names: BIIB 050; KNS-760704; RPPX

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Virginia
  • Developer Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
  • Class Antiparkinsonians; Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome

Most Recent Events

  • 30 Nov 2017 Efficacy data from the phase III EMPOWER trial in Amyotrophic lateral sclerosis released by Cytokinetics
  • 22 Apr 2017 Interim pharmacodynamic data from a phase III trial in Amyotrophic lateral sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 07 Mar 2017 Efficacy data from a phase II trial in Hypereosinophilic syndrome released by Knopp Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top